Daclatasvir is a direct-acting antiviral agent used to treat specific hepatitis C virus (HCV) infections in combination with other antiviral agents. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form.
- Mechanism
- Curator reviewed · 2 references
NS5A is a viral nonstructural phospoprotein that is part of a functional replication complex in charge of viral RNA genome amplification on endoplasmic reticulum membranes. It has the ability to bind to HCV RNA. It is shown to have two distinct functions in HCV RNA replication based on phosphorylated states. Maintaining the HCV replication complex is mediated by the cis-acting function of basally phosphorylated NS5A and the trans-acting function of hyperphosphorylated NS5A modulates HCV assembly and infectious particle formation. Daclatasvir is shown to disrupt hyperphosphorylated NS5A proteins thus interfere with the function of new HCV replication complexes. It is also reported that daclatasvir also blocks both intracellular viral RNA synthesis and virion assembly/secretion in vivo.
- Primary indication
- Indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection.Curator reviewed · 6 structured indications
- Formula / weight
- C40H50N8O6 · 738.89 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2015
- Code names
- BMS 790052 · BMS 790052-05 · EBP-883
Resolves to
FKRSSPOQAMALKA-CUPIEXAXSA-NSMILESCOC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)CWhat you can answer from here — as of October 01, 2026
Which drugs share a target with Daclatasvir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account